Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

Nov 26 2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bladerunner17 who wrote (88)	11/1/2017 1:21:12 PM
From: tuck	Read Replies (1) of 294

ASH abstracts now available, and TRIL has 2. 1/6 OR in DLBCL for monotherapy, but that is a CR. Rituxan combo also yielded a CR, and an overall OR rate of 4/8, the other three responses being partial. From Ansell et. al. In percutaneous solid tumors, clinical activity in all 6 patients, including one CR in a lesion of the foot (three dose sizes; which one this patient got is not given). Querfeld et. al. No AE issues catching my eye in either trial. Disclosure: out of TRIL for a small profit again. Still Watching. Market seems to like these results. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next